Effectiveness of a pilot intervention to reduce abciximab-related bleeding in patients with acute coronary syndromes

详细信息    查看全文

• 作者：Ana de Lorenzo-Pinto (1)
  Héctor Bueno (2)
  Ana Herranz-Alonso (1)
  Jaime Elizaga-Corrales (2)
  Cristina Pérez-Sanz (1)
  Bego?a Cuéllar-Basterrechea (1)
  Francisco Fernández-Avilés (2)
  María Sanjurjo-Sáez (1)
  
• 关键词：Abciximab ; Acute coronary syndrome ; Bleeding ; Cardiology ; Haemorrhage
• 刊名：International Journal of Clinical Pharmacy
• 出版年：2014
• 出版时间：August 2014
• 年：2014
• 卷：36
• 期：4
• 页码：821-826
• 全文大小：173 KB
• 参考文献：1. Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation. 2006;114:774-2. CrossRef
  2. Moscucci M, Fox KA, Cannon CP, Klein W, Lopez-Sendon J, Montalescot G, et al. Predictors of major bleeding in acute coronary syndromes: the global registry of acute coronary events (GRACE). Eur Heart J. 2003;24:1815-3. CrossRef
  3. Rao SV, Eikelboom JW, Granger CB, Harrington RA, Califf RM, Bassand JP. Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes. Eur Heart J. 2007;28:1193-04. CrossRef
  4. ISMP’s List of High-Alert Medications [Internet]. [cited 2011 September 3]. http://www.ismp.org/tools/highalertmedications.pdf.
  5. Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2011;32(23):2999-054. CrossRef
  6. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, et al. 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;123(18):e426-79. CrossRef
  7. National Patient Safety Agency Alert (2010) Rapid response report: NPSA/2010/RRR014: reducing treatment dose errors with low molecular weight heparins. [cited: 2010 December 30]. http://www.nrls.npsa.nhs.uk/resources/?EntryId45=75208.
  8. Hilmer SN, Rangiah C, Bajorek BV, Shenfield GM. Failure to weigh patients in hospital: a medication safety risk. Intern Med J. 2007;37:647-0. CrossRef
  9. Izawa S, Enoki H, Hirakawa Y, Masuda Y, Iwata M, Hasegawa J, et al. Lack of body weight measurement is associated with mortality and hospitalization in community-dwelling frail elderly. Clin Nutr. 2007;26:764-0. CrossRef
  10. De Lorenzo Pinto A, García DL. Weight does matter. Med Clin (Barc). 2011;137(6):259-1. CrossRef
  11. Stone GW, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, Moses JW, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med. 2006;355:2203-6. CrossRef
  12. Mehran R, Lansky AJ, Witzenbichler B. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. Lancet. 2009;374:1149-9. CrossRef
  13. Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium (BARC). Circulation. 2011;123:2736-7. CrossRef
  14. Moscucci M, Fox KA, Cannon CP, Klein W, Lopez-Sendon J, Montalescot G, et al. Predictors of major bleeding in acute coronary syndromes: the global registry of acute coronary events (GRACE). Eur Heart J. 2003;24:1815-3. CrossRef
  15. Berkowitz SD, Granger CB, Pieper KS, Lee KL, Gore JM, Simoons M, et al. Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction. The global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (GUSTO) I investigators. Circulation. 1997;95:2508-6. CrossRef
  16. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045-7. CrossRef
  17. Antman EM, McCabe CH, Gurfinkel EP, Turpie AG, Bernink PJ, Salein D, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation. 1999;100:1593-01. CrossRef
  18. Corbo J, Canter M, Grinberg D, Bijur P. Who should be estimating a patient’s weight in the emergency department? Acad Emerg Med. 2005;12(3):262-. CrossRef
  19. del García MMR, Morales Laborías ME, Fernández López I, Rodríguez Delgado E, Díaz Castellanos MA. Subjective estimation of patient weight and height in the ICU. Non-advisable measures. Med Intensiva. 2013;37:50-. CrossRef
  20. The Clinician’s Ultimate Reference. [cited 2011 Sep 5]. http://www.globalrph.com/abciximab_dilution.htm.
  21. Reopro^?. Summary of product characteristics. [cited 2011 Jun 5]. verFichaWordPdf&codigo=60660&formato=pdf&formulario=FICHAS&file=ficha.pdf" class="a-plus-plus">http://www.aemps.gob.es/cima/especialidad.do?metodo=verFichaWordPdf&codigo=60660&formato=pdf&formulario=FICHAS&file=ficha.pdf.
  22. Alexander KP, Chen AY, Roe MT, Newby LK, Gibson CM, Allen-LaPointe NM, et al. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA. 2005;294(24):3108-6. CrossRef
  
• 作者单位：Ana de Lorenzo-Pinto (1)
  Héctor Bueno (2)
  Ana Herranz-Alonso (1)
  Jaime Elizaga-Corrales (2)
  Cristina Pérez-Sanz (1)
  Bego?a Cuéllar-Basterrechea (1)
  Francisco Fernández-Avilés (2)
  María Sanjurjo-Sáez (1)
  
  1. Pharmacy Department, Instituto de Investigación Sanitaria Gregorio Mara?ón, Hospital General Universitario Gregorio Mara?ón, C/Doctor Esquerdo 46, 28007, Madrid, Spain
  2. Cardiology Department, Instituto de Investigación Sanitaria Gregorio Mara?ón, Hospital General Universitario Gregorio Mara?ón, Madrid, Spain
  
• ISSN：2210-7711

文摘

Background and objective Reducing bleeding events is a priority in patients diagnosed with acute coronary syndromes (ACS). The effectiveness of optimization measures for reducing abciximab-related bleeding was evaluated through the implementation of a pilot program developed by the Pharmacy and the Cardiology Departments at a tertiary-care hospital. Main outcome measure Percentage of bleeding events. Results Intervention was effective in reducing the incidence of the three factors associated with an increased risk of bleeding between the pre-intervention phase (n?=?86) and the post-intervention phase (n?=?73): unknown body weight (24.4 vs. 1.4?%, p?=?0.0001), overdosing (31.4 vs. 0?%, p?p?=?0.016). Bleeding events associated with these factors were numerically reduced in all three cases but these differences were not statistically significant between both periods. Conclusion The implementation of a multidisciplinary prevention program can reduce situations associated with an increased risk of bleeding in patients treated with abciximab. Larger scale trials are needed to confirm whether such programs can also reduce the incidence of bleeding at a statistically significant level.